Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
作者信息
Youssef Soundos, Lavian Jonathan, Lee Eunice Y, Fan Weijia, Bordone Lindsey A
机构信息
Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
出版信息
J Am Acad Dermatol. 2023 May;88(5):1125-1127. doi: 10.1016/j.jaad.2022.05.005. Epub 2022 May 10.
Abstract
摘要
相似文献
1
Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
J Am Acad Dermatol. 2023 May;88(5):1125-1127. doi: 10.1016/j.jaad.2022.05.005. Epub 2022 May 10.
2
Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Dermatol Ther. 2022 Apr;35(4):e15310. doi: 10.1111/dth.15310. Epub 2022 Jan 17.
3
Tofacitinib for the treatment of alopecia areata and variants in adolescents.
J Am Acad Dermatol. 2017 Jan;76(1):29-32. doi: 10.1016/j.jaad.2016.09.006. Epub 2016 Nov 2.
4
Alopecia areata flare patterns in children and young adults while on systemic tofacitinib.
J Am Acad Dermatol. 2022 Mar;86(3):683-685. doi: 10.1016/j.jaad.2021.02.071. Epub 2021 Mar 2.
5
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Dermatology. 2019;235(2):130-136. doi: 10.1159/000494613. Epub 2018 Dec 19.
6
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
J Am Acad Dermatol. 2017 Jan;76(1):22-28. doi: 10.1016/j.jaad.2016.09.007. Epub 2016 Nov 2.
7
Systematic review - alopecia areata and tofacitinib in paediatric patients.
Cutan Ocul Toxicol. 2022 Jun;41(2):194-201. doi: 10.1080/15569527.2022.2084622. Epub 2022 Jun 10.
8
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
Dermatol Ther. 2021 Mar;34(2):e14746. doi: 10.1111/dth.14746. Epub 2021 Jan 18.
9
Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Dermatol Ther. 2022 Dec;35(12):e15871. doi: 10.1111/dth.15871. Epub 2022 Dec 1.
10
Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
Acta Derm Venereol. 2023 Dec 19;103:adv12425. doi: 10.2340/actadv.v103.12425.
本文引用的文献
1
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Clin Cosmet Investig Dermatol. 2021 Jun 25;14:691-714. doi: 10.2147/CCID.S309215. eCollection 2021.
2
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.
PLoS One. 2021 Mar 4;16(3):e0247461. doi: 10.1371/journal.pone.0247461. eCollection 2021.
3
Validation of Case Identification for Alopecia Areata Using International Classification of Diseases Coding.
Int J Trichology. 2020 Sep-Oct;12(5):234-237. doi: 10.4103/ijt.ijt_67_20. Epub 2020 Nov 3.
4
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
Dermatol Ther. 2021 Mar;34(2):e14746. doi: 10.1111/dth.14746. Epub 2021 Jan 18.
5
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
Zotero 插件